Type 2 Diabetes Drug Linagliptin (Tradjenta) Lowers Blood Sugar Levels for Patients and Carries less Risk for Weight Gain, Heart Attack and Stroke
The Traditional first-line treatment for type 2 diabetes uses the drug metformin (Glucophage) to help control blood sugar levels. Some patients may stop responding to this drug or require supplemental drugs (sulphonylureas) in order to see benefits.
Recent studies show that compared to traditional supplemental drugs, a new second-line treatment for type 2 diabetes, linagliptin (Tradjenta), not only lowers blood sugar but carries less risk for hypoglycemia and weight gain, both of which can lead to heart attack and stroke.
In a German study, researchers examined the effects of linagliptin and glimepiride, the most commonly used sulphonylurea, in 1500 patients with type 2 diabetes. Only seven percent of patients on linagliptin experienced hypoglycemia in contrast to 38 percent of patients on glimepiride.
A separate study out of the United Kingdom found that adding linagliptin to metformin, in combination with sulphonylurea, significantly improved glycemic control, making this therapy a viable option for patients with ongoing problems controlling blood sugar levels.
Further, scientists at Washington State University observed that linagliptin treatment does not require dosage adjustments in patients with kidney or liver impairment. Once-daily, oral doses of 5 mg have proven effective and well-tolerated and do not increase a patient’s risks for weight gain.
Medify, which has over 4,580 research abstracts on metformin alone, is on a mission to provide patients and their loved ones access to the best information online about their medical condition.
- Pharmacology, Efficacy, and Safety of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
- Efficacy and Safety of Linagliptin in Persons with Type 2 Diabetes
- Cardiovascular Safety with Linagliptin in Patients with Type 2 Diabetes Mellitus
- Linagliptin, Tradjenta
- Linagliptin Noninferior to Glimepiride in Type 2 Diabetes
Powered by Facebook Comments